- NHL Treatment
- Hodgkin's Treatment
- Clinical Trials
- Monoclonal Antibodies
- Types of NHL
Lymphoma and Pets
Drug for peripheral T-cell lymphoma granted orphan drug status
The US FDA has granted orphan drug status to Boston-based Ziopharm Oncology for the company's experimental drug darinaparsin for the treatment of peripheral T-cell lymphoma (PTCL).
Ziopharm will soon begin to recruit patients for a phase I trial of darinaparsin as an added component of the combination chemotherapy regimen CHOP.